KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $76.6 million.

  • AbCellera Biologics' Total Current Liabilities fell 13.53% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 13.53%. This contributed to the annual value of $76.6 million for FY2024, which is 35.63% down from last year.
  • Per AbCellera Biologics' latest filing, its Total Current Liabilities stood at $76.6 million for FY2024, which was down 35.63% from $119.0 million recorded in FY2023.
  • AbCellera Biologics' Total Current Liabilities' 5-year high stood at $120.7 million during FY2021, with a 5-year trough of $76.6 million in FY2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $118.3 million (2022), whereas its average is $104.6 million.
  • In the last 5 years, AbCellera Biologics' Total Current Liabilities climbed by 16.61% in 2021 and then tumbled by 35.63% in 2024.
  • Over the past 5 years, AbCellera Biologics' Total Current Liabilities (Yearly) stood at $103.5 million in 2020, then rose by 16.61% to $120.7 million in 2021, then decreased by 1.95% to $118.3 million in 2022, then increased by 0.59% to $119.0 million in 2023, then plummeted by 35.63% to $76.6 million in 2024.